SCHEMBL5527093

SCHEMBL5527093

O=C(O)c1cc(/C=C/c2ccc(O)cc2)[nH]n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 3/20 0.68
▸ NPC1 O15118 2/20 0.56
▸ POLB P06746 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ HCAR2 Q8TDS4 5/20 0.56
▸ TTR P02766 2/20 0.49
▸ MAOB P27338 3/20 0.46
▸ APP P05067 3/20 0.46
▸ MAOA P21397 2/20 0.46
▸ CA12 O43570 3/20 0.46
▸ CA1 P00915 3/20 0.46
▸ CA2 P00918 3/20 0.46
▸ CA3 P07451 3/20 0.46
▸ CA4 P22748 3/20 0.46
▸ CA6 P23280 3/20 0.46
▸ CA5A P35218 3/20 0.46
▸ CA7 P43166 3/20 0.46
▸ CA9 Q16790 3/20 0.46
▸ CA14 Q9ULX7 3/20 0.46
▸ CA5B Q9Y2D0 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5527097 1.00 PTGS2 (0.68) PTGS2NPC1POLBRAB9AHCAR2
SCHEMBL9454573 0.88 POLB (0.70) PTGS2NPC1POLBRAB9AHCAR2
SCHEMBL9454564 0.88 POLB (0.70) PTGS2NPC1POLBRAB9AHCAR2
SCHEMBL14342645 0.83 NPC1 (0.77) PTGS2NPC1POLBRAB9ATTR
SCHEMBL1793302 0.79 PTGS2 (0.87) PTGS2NPC1POLBRAB9ATTR
SCHEMBL14342572 0.79 PTGS2 (0.87) PTGS2NPC1POLBRAB9ATTR
SCHEMBL1793300 0.79 PTGS2 (0.87) PTGS2NPC1POLBRAB9ATTR
SCHEMBL1793303 0.79 PTGS2 (0.87) PTGS2NPC1POLBRAB9ATTR
SCHEMBL14342575 0.76 PTGS2 (0.67) PTGS2NPC1POLBRAB9ATTR
SCHEMBL5599558 0.75 HCAR2 (0.63) NPC1POLBRAB9AHCAR2DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710038-B2 Pyrazole kinase modulators and methods of use EXELIXIS, INC. (US) 2014-04-29 — — US disclosed
US-8710038-B2 Pyrazole kinase modulators and methods of use EXELIXIS, INC. (US) 2014-04-29 — — US disclosed
US-8710038-B2 Pyrazole kinase modulators and methods of use EXELIXIS, INC. (US) 2014-04-29 — — US disclosed
US-20070293507-A1 Pyrazole Kinase Modulators And Methods Of Use EXELIXIS, INC. (US) 2007-12-20 — — US disclosed
US-20070293507-A1 Pyrazole Kinase Modulators And Methods Of Use EXELIXIS, INC. (US) 2007-12-20 — — US disclosed
US-20070293507-A1 Pyrazole Kinase Modulators And Methods Of Use EXELIXIS, INC. (US) 2007-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293507-A1 Pyrazole Kinase Modulators And Methods Of Use MAP3K1, MAP3K3, MAP3K5 PTGS2 768/4885NPC1 2422/4885POLB 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback